TY - JOUR
T1 - Explore, visualize, and analyze functional cancer proteomic data using the cancer proteome atlas
AU - Li, Jun
AU - Akbani, Rehan
AU - Zhao, Wei
AU - Lu, Yiling
AU - Weinstein, John N.
AU - Mills, Gordon B.
AU - Liang, Han
N1 - Funding Information:
This study was supported by the NIH (CA168394, CA098258, CA143883 and HG008100 to G.B. Mills; CA175486 to H. Liang; CA209851 to H. Liang and G.B. Mills; CA201949 and CA210950 to G.B. Mills, R. Akbani, and J.N. Weinstein; and the MD Anderson Cancer Center Support grant, CA016672), a grant from the Cancer Prevention and Research Institute of Texas (RP140462 to H. Liang), the Lorraine Dell Program in Bioinformatics for Personalization of Cancer Medicine (to J. N. Weinstein), and the Adelson Medical Research Foundation (to G.B. Mills).
Publisher Copyright:
© 2017 American Association for Cancer Research.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Reverse-phase protein arrays (RPPA) represent a powerful functional proteomic approach to elucidate cancer-related molecular mechanisms and to develop novel cancer therapies. To facilitate community-based investigation of the large-scale protein expression data generated by this platform, we have developed a user-friendly, open-access bioinformatic resource, The Cancer Proteome Atlas (TCPA, http://tcpaportal.org), which contains two separate web applications. The first one focuses on RPPA data of patient tumors, which contains >8, 000 samples of 32 cancer types from The Cancer Genome Atlas and other independent patient cohorts. The second application focuses on the RPPA data of cancer cell lines and contains >650 independent cell lines across 19 lineages. Many of these cell lines have publicly available, high-quality DNA, RNA, and drug screening data. TCPA provides various analytic and visualization modules to help cancer researchers explore these datasets and generate testable hypotheses in an effective and intuitive manner. Cancer Res; 77(21); e51-54.
AB - Reverse-phase protein arrays (RPPA) represent a powerful functional proteomic approach to elucidate cancer-related molecular mechanisms and to develop novel cancer therapies. To facilitate community-based investigation of the large-scale protein expression data generated by this platform, we have developed a user-friendly, open-access bioinformatic resource, The Cancer Proteome Atlas (TCPA, http://tcpaportal.org), which contains two separate web applications. The first one focuses on RPPA data of patient tumors, which contains >8, 000 samples of 32 cancer types from The Cancer Genome Atlas and other independent patient cohorts. The second application focuses on the RPPA data of cancer cell lines and contains >650 independent cell lines across 19 lineages. Many of these cell lines have publicly available, high-quality DNA, RNA, and drug screening data. TCPA provides various analytic and visualization modules to help cancer researchers explore these datasets and generate testable hypotheses in an effective and intuitive manner. Cancer Res; 77(21); e51-54.
UR - http://www.scopus.com/inward/record.url?scp=85034996912&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85034996912&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-17-0369
DO - 10.1158/0008-5472.CAN-17-0369
M3 - Article
C2 - 29092939
AN - SCOPUS:85034996912
SN - 0008-5472
VL - 77
SP - e51-e54
JO - Cancer Research
JF - Cancer Research
IS - 21
ER -